Merck slides on odanacatib delay despite 'reasonable guidance' for 2013
22:35 EST 3 Feb 2013 | SCRIP
Merck's 2012 earnings report, in which the company would have had positive sales growth without the negative impact of foreign exchange rates, was overshadowed by the announcement that a planned 2013 new drug application (NDA) to the US FDA for the...
Original Article: Merck slides on odanacatib delay despite 'reasonable guidance' for 2013
More From BioPortfolio on "Merck slides on odanacatib delay despite 'reasonable guidance' for 2013"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
